Study type: In vivo/preclinical · Status: Verified against declared source
Evaluation of the therapeutic potential of cerebrolysin and/or lithium in the male Wistar rat model of Parkinson's disease induced by reserpine.
Metabolic brain disease · 2023
Study scale: Values represent mean ± S.E.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide and represents a challenge for clinicians.
Methods
According to the method of Ruiz-Larrea et al.
Scale or participants
Values represent mean ± S.E.
Key findings
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide and represents a challenge for clinicians.
Limitations and uncertainty
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease worldwide and represents a challenge for clinicians.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.